儿童非转移性单侧视网膜母细胞瘤的治疗策略研究
该单臂前瞻性多中心研究在拉丁美洲纳入175例可评估的非转移性单侧视网膜母细胞瘤患儿,依据分期和病理风险分层给予保守治疗、辅助化疗或新辅助化疗,中位随访46个月时3年无事件生存概率为0.97,总生存概率为0.98。
要点
- 3年无事件生存概率0.97(95%CI 0.94-0.99),总生存概率0.98(95%CI 0.94-1.00)。
- 高危组接受辅助化疗,低危组未接受辅助治疗,眼球突出组接受新辅助加辅助化疗共8周期。
- 辅助治疗对高危单侧视网膜母细胞瘤可能有效但有毒性,眼球突出新辅助化疗似乎可行。
核心结论
- 辅助治疗对高危单侧视网膜母细胞瘤可能有效但有毒性,眼球突出新辅助化疗似乎可行。
研究设计与样本
- 单臂前瞻性研究,基于单中心经验制定策略,在拉丁美洲GALOP多中心开展。
- 纳入非转移性单侧视网膜母细胞瘤患儿,采用国际视网膜母细胞瘤分期系统分期。
- 187例注册,175例可评估(92例女性,52.5%;中位年龄22月,范围3-100月)。
主要发现
- 中位随访46个月,3年无事件生存概率0.97(95%CI 0.94-0.99),总生存概率0.98(95%CI 0.94-1.00)。
- 0期42例无事件;I期低危84例中1例事件(眶复发后二线治疗)。
- I期高危42例中2例事件(1例中枢神经系统复发,1例脓毒症死亡);眼球突出组7例中1例事件(眶复发后中枢神经复发并死亡)。
关键数值与推荐
- 0期(未行眼球摘除)接受保守治疗,无方案。
- I期(眼球摘除无残留肿瘤)分高危组(后板层侵犯和/或巩膜侵犯)和低危组(其余)。
- 高危组接受辅助化疗:方案1(环磷酰胺65 mg/kg/d[加美司钠]、伊达比星10 mg/m2/d、长春新碱0.05 mg/kg/d)与方案2(卡铂500 mg/m2/d,第1-2天;依托泊苷100 mg/m2/d,第1-3天)交替4周期,共8周期。
- 低危组不接受辅助治疗;眼球突出组接受新辅助和辅助化疗共8周期。
临床怎么用
- 该策略依据分期和病理风险分层实施辅助化疗,高危组接受8周期交替方案化疗。
- 低危组未接受辅助治疗,0期患者接受保守治疗。
- 眼球突出患者接受新辅助和辅助化疗共8周期。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multi-institutional collaborative studies that include large patient populations for the management of retinoblastoma with histopathological risk factors could provide important information for patient management. OBJECTIVE: To evaluate the implementation of a strategy for the management of nonmetastatic unilateral retinoblastoma in children based on standardized diagnostic and treatment criteria. DESIGN, SETTING, AND PARTICIPANTS: This single-arm prospective study applied a strategy based on a single-center experience. The setting was a multicenter study in Latin America (Grupo de America Latina de Oncologia Pediatrica [GALOP]). Participants were children with nonmetastatic unilateral retinoblastoma (staged with the International Retinoblastoma Staging System). The study opened on July 1, 2008, and closed on December 31, 2014. Follow-up was updated until June 30, 2017. INTERVENTIONS: Stage 0 patients (without enucleation) were given conservative therapy without a protocol. Stage I patients (with enucleation and no residual tumor) were divided into a high-risk group (retrolaminar invasion and/or scleral invasion) and a low-risk group (all remaining patients). High-risk children received adjuvant chemotherapy with 4 alternating cycles of regimen 1 (cyclophosphamide [65 mg/kg/d] [plus sodium-2-mercaptoethane sulfonate], idarubicin hydrochloride [10 mg/m2/d], and vincristine sulfate [0.05 mg/kg/d]) and 4 cycles of regimen 2 (carboplatin [500 mg/m2/d, days 1 and 2] and etoposide [100 mg/m2/d, days 1-3]). Low-risk children did not receive adjuvant therapy. Children with buphthalmia received neoadjuvant and adjuvant chemotherapy for a total of 8 cycles. MAIN OUTCOMES AND MEASURES: Probability of event-free survival (extraocular relapse and death from any cause were considered events). RESULTS: Among 187 children registered in the study, 175 were evaluable (92 [52.5%] female; median age, 22 months; age range, 3-100 months). Forty-two were stage 0 children, 84 were stage I low-risk children, and 42 were stage I high-risk children; there were 7 children in the buphthalmia group. With a median follow-up of 46 months, the 3-year probability of event-free survival was 0.97 (95% CI, 0.94-0.99), and the probability of overall survival was 0.98 (95% CI, 0.94-1.00). Stage 0 patients had no events, stage I low-risk patients had 1 event (orbital relapse treated with second-line therapy), stage I high-risk patients had 2 events (1 central nervous system relapse and 1 death from sepsis), and the buphthalmia group had 1 event (orbital relapse, followed by central nervous relapse and death). CONCLUSIONS AND RELEVANCE: Adjuvant therapy may be effective for high-risk unilateral retinoblastoma but is toxic, and neoadjuvant chemotherapy for buphthalmus appears feasible.
引用
- Pérez V, Sampor C, Rey G, et al. Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. JAMA Ophthalmol. 2018. PMID: 29799944. doi:10.1001/jamaophthalmol.2018.1501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。